Breast Oncology

乳腺肿瘤学

• 批准号: 8696607
• 负责人: MAX S. WICHA
• 金额: $ 15.48万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8696607
• 关键词: Address; Adjuvant Chemotherapy; Africa; African American; Aggressive behavior; Appointment; Area; Automobile Driving; Basic Science; Bioinformatics; Biological; Biological Factors; Biological Sciences; Biomechanics; Biomedical Engineering; Biometry; Blue Cross; Blue Shield; Breast; Breast Cancer Genetics; Breast Cancer Treatment; Cancer Center; Cancer Center Support Grant; Cancer Survivorship; Cells; Cessation of life; Clinical; Clinical Research; Clinical Trials; Collaborations; Communities; Complex; Computational Biology; Continuance of life; Coupled; DNA Repair; DNA Sequence; DNA Sequencing Facility; Data; Development; Developmental Therapeutics Program; Devices; Diagnosis; Diagnostic; Doctor of Medicine; Drosophila chb protein; Drug Kinetics; Engineering; Ensure; Epithelial; Evaluation; Event; Faculty; Flow Cytometry; Foundations; Free Energy; Fund Raising; Funding; Future; Generations; Genes; Ghana; Goals; Grant; Health; Health Services Research; Hematology; Hospitals; Informatics; Institute of Medicine (U.S.); Institutes; International Agencies; Joints; Laboratories; Lead; Leadership; Malignant - descriptor; Malignant Neoplasms; Mammary Gland Parenchyma; Mechanics; Mediation; Medicine; Mesenchymal; Metabolism; Methods; Michigan; Middle East; Modeling; Molecular; Molecular Genetics; Monitor; Nanotechnology; Neoplasm Circulating Cells; Neoplasm Metastasis; Outcome; Outcomes and Health Services Research; Pathway interactions; Patients; Peer Review; Pharmacogenetics; Phase; Phase I Clinical Trials; Population; Positioning Attribute; Prevention; Prevention strategy; Process; Proteins; Publications; Quality of life; Recruitment Activity; Regulation; Research; Research Personnel; Research Project Grants; Resistance; Risk Assessment; Risk Management; Role; Schools; Science; Sister; Site; Teaching Hospitals; Text; Therapeutic; Training Activity; Transcriptional Regulation; Translational Research; Universities; University of Michigan Comprehensive Cancer Center; Woman; Work; Xenograft procedure; anticancer research; cancer cell; cancer education; cancer stem cell; cell motility; chemokine; chemotherapy; college; community setting; drug development; drug discovery; frontier; gamma secretase; genetic epidemiology; global health; improved; inhibitor-of-apoptosis protein; inhibitor/antagonist; malignant breast neoplasm; medical schools; meetings; member; model development; molecular imaging; new therapeutic target; next generation sequencing; novel; novel diagnostics; novel therapeutics; oncology; oncology program; outcome forecast; pre-clinical; preclinical study; programs; stem; stem cell population; survivorship; tool development; triple-negative invasive breast carcinoma; tumor; tumorigenesis; working group

The Breast Oncology Program (BOP), co-directed by Daniel F. Hayes, M.D. and Sofia D. Merajver, M.D., conducts basic, translational, and clinical research covering the spectrum of breast cancer. The BOP has six major scientific themes: 1) elucidation of the molecular mechanism of regulation of normal and malignant breast tissues and cells; 2) development of tools for diagnosis, prognosis, and monitoring; 3) development of novel therapeutic strategies; 4) evaluation of risk assessment and prevention strategies; 5) Improvement in quality of life and survivorship issues for patients with breast cancer; and 6) health services research. The BOP has 49 members from 11 Departments within.5 Schools of the University of Michigan, ensuring broad multi-disciplinary collaborations. Indeed, of the 397 publications by program members over this grant period, 20% were Intra-programmatic and 44% were inter-programmatic collaborations. Members of the UM BOP receive over $14,2 million In annual direct peer-reviewed funding of which $4 million Is from the NCI. During this period, BOP investigators have 1) characterized the breast cancer stem cell and conducted a phase 1 trial of chemotherapy plus a gamma secretase Inhibitor, 2) performed pre-clinical studies and Introduced a novel agent that inhibits the inhibitor of apoptosis proteins (lAPs) into clinical trial; 3) studied RhoC proteins, cancer cell matrix transport, epithelial-mesenchymal transition, and chemokine mediation of metastasis; 4) performed pre- and clinical studies of circulating tumor cells; 5) advanced understanding of transcriptional regulation, DNA repair, and cancer genetics, of breast epithelial tumorigenesis; 6) Identified translocations involving the MAST and NOTCH genes 7) demonstrated intrinsic subtypes that are resistant to adjuvant chemotherapy; 8) Investigated pharmacogenetics of breast cancer treatment; and 9) furthered the breast cancer survivorship and quality of life. The BOP has a major commitment to health services and outcomes research, with Important observations regarding patient decision. The BOP will continue these important pre-clinical, translational, and clinical studies in the upcoming funding period, particularly focusing on discovery of new diagnostic and therapeutic targets.

乳腺肿瘤学项目（BOP）由Daniel F. Hayes医学博士和Sofia D. Merajver医学博士共同指导，开展涵盖乳腺癌谱的基础、转化和临床研究。BOP有六个主要的科学主题：1)阐明正常和恶性乳腺组织和细胞调节的分子机制；2)诊断、预后和监测工具的开发；3)开发新的治疗策略；4)评价风险评估和预防策略；5)改善乳腺癌患者的生活质量和生存问题；6)健康服务研究。BOP有来自11个部门的49名成员确保广泛的多学科合作。事实上，在此资助期间，项目成员的397份出版物中，20%是项目内部合作，44%是项目间合作。umbop成员每年获得超过1420万美元的直接同行评审资金，其中400万美元来自NCI。在此期间，BOP研究人员1)对乳腺癌干细胞进行了表征，并开展了化疗加γ分泌酶抑制剂的一期试验；2)进行了临床前研究，并将一种抑制凋亡蛋白抑制剂（lAPs）的新型药物引入临床试验；3)研究RhoC蛋白、癌细胞基质转运、上皮-间质转化、趋化因子介导的转移；4)循环肿瘤细胞的前期和临床研究；5)对乳腺上皮肿瘤发生的转录调控、DNA修复和癌症遗传学的深入了解；6)已确定的涉及MAST和NOTCH基因的易位7)显示出对辅助化疗耐药的内在亚型；8)乳腺癌治疗的药物遗传学研究；9)提高乳腺癌患者的生存率和生活质量。BOP主要致力于卫生服务和成果研究，并对患者的决定进行重要观察。在即将到来的资助期内，BOP将继续进行这些重要的临床前、转化和临床研究，尤其侧重于发现新的诊断和治疗靶点。